Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival
Maybury, Bernard D James, Lisa J Phillips, Neil Venkatadasari, Indrani Qureshi, Iman Riley, James Talbot, Georgina Moosai, Shivir Giles, Hannah Chadderton, Nicola
Maybury, Bernard D
James, Lisa J
Phillips, Neil
Venkatadasari, Indrani
Qureshi, Iman
Riley, James
Talbot, Georgina
Moosai, Shivir
Giles, Hannah
Chadderton, Nicola
Citations
Altmetric:
Affiliation
University Hospitals Birmingham NHS Foundation Trust; University Hospitals of the North Midlands NHS Trust; The Royal Wolverhampton NHS Trust; University Hospitals Coventry and Warwickshire NHS Foundation Trust; The Dudley Group NHS Foundation Trust; Shrewsbury and Telford Hospital NHS Trust; Walsall Healthcare NHS Trust; Sandwell and West Birmingham Hospitals NHS Trust
Other Contributors
Publication date
2024-07-04
Subject
Research Projects
Organizational Units
Journal Issue
Abstract
A reciprocal t(3;8) BCL6::MYC fusion is common in large B cell lymphoma (LBCL) with MYC and BCL6 disruption. These pseudo-double hit cases are not adverse, whereas t(3;8) negative MYC/BCL6 lymphoma has an inferior prognosis relative to other MYC-rearranged LBCL.
Citation
Maybury BD, James LJ BSc (Hons), Phillips N, Venkatadasari I, Qureshi I, Riley JWE, Talbot G, Moosai S, Giles HV Dr, Chadderton N Mrs, Dowds J, Rakesh P, Crosland H, Haslam A, Lane S, Vega Gonzalez M, Davies D, Cherian G, Shenouda A, Kaudlay Sathyanarayana PK, Starczynski J, Rudzki Z, Chaganti S. Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival. Blood. 2024 Apr 22:blood.2024024048.
Type
Article